Argenx Stock Sinks on Scrapped Autoimmune Drug Trial. Why the Selloff Is Overdone.
Argenx says it discontinued a late-stage clinical trial in patients with Sjögren’s disease at the recommendation of an independent committee. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF SEPTEMBER 30, 2026
Klépierre INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF SEPTEMBER 30, 20261 Paris – October 8, 2026 NUMBER OF SHARES AS OF SEPTEMBER 30, 2026 Date 09/30/2026 Company name Klépierre Trading place Euronext Pa…
Argenx Stock Sinks as Scrapped Vyvgart Trial Erases $3.5 Billion Opportunity
Argenx says it discontinued a late-stage clinical trial in patients with Sjögren’s disease at the recommendation of an independent committee. Continue Reading
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Novartis NVS received a key regulatory win for Rhapsido (remibrutinib) in the United States, with the FDA approving the oral Bruton's tyrosine kinase (BTK) inhibitor for adults with symptomatic dermographism (SD) inadequately controlled by…
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response. Continue Reading
Pheochromocytoma and Paraganglioma (PCPG) Market to Reach US$670 Million by 2036 at 7.3% CAGR, Driven by Targeted and Radioligand Therapies
Company Logo Up from about US$300 million in 2025 across the US, EU4, UK and Japan, as Merck's WELIREG, the first oral targeted PCPG therapy, faces pipeline rivals from Novartis, Jazz and Perspective. Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE)…
Alphabet’s Isomorphic Labs in Funding Talks for at Least $40 Billion Value
(Bloomberg) -- Isomorphic Labs, an AI-powered drug discovery startup spun out of Alphabet Inc.'s Google DeepMind, is in early talks to raise new funds at a valuation of at least $40 billion, according to people familiar with the effort. Mo…
VERBUND AG: Stefan Waldner Appointed Chief Financial Officer
VIENNA, AUSTRIA - October 7, 2026 (NEWMEDIAWIRE) - The Supervisory Board of VERBUND AG today appointed Stefan Waldner (49) as Chief Financial Officer (CFO) and a member of the Management Board. His appointment is for a two-year term, with…
Is Novartis (SWX:NOVN) Undervalued After New MS Trial Data Took Center Stage?
Novartis (SWX:NOVN) just put multiple sclerosis front and center for investors, flagging 46 abstracts for MSToronto2026, including late breaking Phase III REMODEL data on remibrutinib and new Kesimpta pediatric results. At a share price of…
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 1.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Norwegian Air Shuttle (OB:NAS) Adds 737 8 Capacity On A Fair Value Gap Narrative
Norwegian Air Shuttle's New 737-8 Deliveries Set Up Fresh Capacity Questions CDB Aviation has delivered the first of four Boeing 737-8 jets to Norwegian Air Shuttle (OB:NAS), kicking off a new leasing partnership and adding aircraft tied t…
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
Novartis Pharma AG In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21 SD is most prevalent type of chronic inducible urticaria (CIndU)2; m…
Rivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment
Founded by serial entrepreneur and CEO, Yann Fleureau, and former AI research leader at Novartis and Owkin Eric Durand, Rivercell aims to generate high-resolution data on how human cells respond to treatments at scale and train AI models t…
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Novartis Pharma AG Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and remibrutinib in MS Phase I…
Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases
Matchpoint Therapeutics Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in 2027 WATER…
Pacibekitug Market Size, Sales Forecast, and Competitive Analysis - 2034 | Phase III-Ready IL-6 Therapy Targets Major Cardiovascular Growth Opportunities in the 7MM
Company Logo Pacibekitug combines strong Phase II efficacy, quarterly dosing, a large residual-risk population and Novartis' reach—key drivers of adoption and market positioning. Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Pacibekitug Sales…
Novartis (SWX:NOVN) Stock May Trade Below Fair Value As Digital CMC News Lands
Novartis has delivered a strong multi year run, so with the stock recently changing hands around US$117 the live question is whether that price still lines up with what its earnings can justify. After a pullback in recent weeks, the focus…
Information Regarding the Total Voting Rights and Shares of Gecina as of September 30, 2026 (1)
PARIS, October 06, 2026--(BUSINESS WIRE)--Regulatory News: Gecina (Paris:GFC): Date Total number of shares Total number of voting rights September 2026 76,792,337 Total number of voting rights (including treasury shares): 76,792,337 Total…
Klépierre: Disclosure of transactions in own shares from September 30 to October 2, 2026
Klépierre DISCLOSURE OF TRANSACTIONS IN OWN SHARES FROM SEPTEMBER 30 TO OCTOBER 2, 2026 Paris – October 6, 2026 As part of the implementation of the treasury share buyback program authorized by the Shareholders' General Meeting Meeting of…
RAMSAY SANTE : Final annual results as of 30 June 2026
RAMSAY SANTE PRESS RELEASE Paris, 6th October 2026 Annual results at the end of June 2026 Revenue growth and disciplined efficiency drive stronger operational profitability Capital Markets Day on 17th September: Ramsay Santé outlined its n…
SAP Puts the Autonomous Enterprise to Work
Joule Work, Joule Assistants and SAP Business AI Platform help organizations turn business AI into trusted outcomes across every core function. LAS VEGAS, Oct. 6, 2026 /PRNewswire/ -- SAP SE (NYSE: SAP) today showcased the Autonomous Enter…
Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium
Uniting industry leaders to build the digital standards and infrastructure needed for the future of drug development DOVER, Del., Oct. 6, 2026 /PRNewswire/ -- The Digital CMC Consortium today launched as a new industry collaboration unitin…
Norwegian Air September traffic climbs 7% on strong autumn demand
Investing.com -- Norwegian Air Shuttle said Monday its September load factor rose to 87.1%, up 0.6 percentage points from a year earlier, as strong autumn holiday demand across the Nordic countries filled flights and early winter bookings…
3 Multinational Stocks Retail Investors Are Watching As Trade Risks Rise
Global markets are being pulled in several directions at once as central banks rethink policy, trade rules are rewritten and geopolitics keeps volatility on a short fuse. That mix can punish weaker businesses and reward multinationals buil…
What's next for personalized mRNA cancer vaccines?
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Swiss pharma giant Novartis NVS entered into a licensing and option agreement with China-based Abogen Biosciences in a bid to expand its presence in RNA-based therapeutics. The deal gives Novartis exclusive worldwide rights to Abogen's lea…
GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition
GE Healthcare Technologies will purchase radiopharmaceutical company Sofie Biosciences to expand into a lucrative therapeutic area. Continue Reading
HighCo: SHAREHOLDING
HIGHCO INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des marchés financiers (AMF) Date of…
Notable healthcare headlines for the week: Pfizer, Sanofi, and Novartis in focus
Wall Street closed in the green on Friday after the September nonfarm payrolls report came in cooler than economists expected. The blue-chip Dow ended up 0.5%, the benchmark S&P 500 gained 0.7%, and the tech-focused Nasdaq Composite advanc…
NKT (CPSE:NKT) Stock Sees Modest Fair Value Lift After More Balanced Analyst Views
NKT now sits against an updated fair value of DKK 952.88 compared with DKK 915.46 previously, which places the internal pricing anchor closer to the DKK 895 to DKK 917 range used in recent Street targets. With most analysts clustered aroun…
Tecan Group Stock Sees Modest Fair Value Lift After Analyst Target Increases
Tecan Group is back in focus after analysts lifted their fair value estimate from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Several firms have adjusted targets between CHF 151 and CHF 240, with some…
Sector Update: Healthcare Stocks Steady Late Afternoon
Healthcare stocks were little changed late Friday afternoon with the NYSE Healthcare Index and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Agios Pharmaceuticals AGIO is entering an important phase of its growth story as its lead therapy, mitapivat, expands across multiple blood disorders. The drug is marketed as Pyrukynd for pyruvate kinase (PK) deficiency and as Aqvesme for…
Novartis inks up to $7.8B deal with Abogen for RNA-encoded therapeutics
[Novartis Corporate Building with Solar Panels] Ellads * China's Abogen Biosciences has entered into a licensing and option agreement with Novartis (NVS [https://seekingalpha.com/symbol/NVS]) to advance RNA-encoded therapeutics, according…
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other potential programs leveraging Abogen's RNA proprietary platform SUZHOU, China, Oct. 2, 20…